Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours

Background Genetic alterations in fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) signalling are observed in various tumours. We report a first-in-human phase I/IIa trial evaluating tolerability, pharmacokinetics and preliminary antitumour activity of...

Full description

Bibliographic Details
Main Authors: Rebecca S Kristeleit, Antoine Italiano, Petri Bono, Giuseppe Curigliano, Analia Azaro, Katriina J Peltola, Pasi Hakulinen, Chris Garratt, Tarja Ikonen, Mika V J Mustonen
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/5/6/e001081.full

Internet

https://esmoopen.bmj.com/content/5/6/e001081.full

Similar Items